These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27341035)

  • 41. [Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].
    Zheng Q; Zhu YY; Chen J; Liu YR; You J; Zeng DW; Lin S; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Nov; 20(11):801-6. PubMed ID: 23206296
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection.
    Fisicaro P; Valdatta C; Boni C; Massari M; Mori C; Zerbini A; Orlandini A; Sacchelli L; Missale G; Ferrari C
    Gut; 2009 Jul; 58(7):974-82. PubMed ID: 19201769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B.
    Tjwa ET; van Oord GW; Hegmans JP; Janssen HL; Woltman AM
    J Hepatol; 2011 Feb; 54(2):209-18. PubMed ID: 21095036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-HBV activity and mechanism of marine-derived polyguluronate sulfate (PGS) in vitro.
    Wu L; Wang W; Zhang X; Zhao X; Yu G
    Carbohydr Polym; 2016 Jun; 143():139-48. PubMed ID: 27083353
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections.
    Oliviero B; Varchetta S; Paudice E; Michelone G; Zaramella M; Mavilio D; De Filippi F; Bruno S; Mondelli MU
    Gastroenterology; 2009 Sep; 137(3):1151-60, 1160.e1-7. PubMed ID: 19470388
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between CISH polymorphisms and spontaneous clearance of hepatitis B virus in hepatitis B extracellular antigen-positive patients during immune active phase.
    Song G; Rao H; Feng B; Wei L
    Chin Med J (Engl); 2014; 127(9):1691-5. PubMed ID: 24791876
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection.
    Jang JW; Yoo SH; Kwon JH; You CR; Lee S; Lee JH; Chung KW
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1337-46. PubMed ID: 22007836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Occult hepatitis B virus infection with positive hepatitis B e antigen.
    Han Z; Liu Y; Pan J; Bi Y; Liu J; Zhou YH
    Clin Chim Acta; 2015 Jan; 438():266-8. PubMed ID: 25218700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impaired function of hepatic natural killer cells from murine chronic HBsAg carriers.
    Chen Y; Wei H; Sun R; Tian Z
    Int Immunopharmacol; 2005 Dec; 5(13-14):1839-52. PubMed ID: 16275620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
    Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.
    Salpini R; Colagrossi L; Bellocchi MC; Surdo M; Becker C; Alteri C; Aragri M; Ricciardi A; Armenia D; Pollicita M; Di Santo F; Carioti L; Louzoun Y; Mastroianni CM; Lichtner M; Paoloni M; Esposito M; D'Amore C; Marrone A; Marignani M; Sarrecchia C; Sarmati L; Andreoni M; Angelico M; Verheyen J; Perno CF; Svicher V
    Hepatology; 2015 Mar; 61(3):823-33. PubMed ID: 25418031
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay.
    Chung KH; Kim W; Kim BG; Lee HY; Jin E; Cho Y; Seo JY; Kim HY; Jung YJ; Kim JW; Jeong JB; Lee KL
    Gut Liver; 2015 Sep; 9(5):657-64. PubMed ID: 25717049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic potential of furin inhibitors for the chronic infection of hepatitis B virus.
    Pang YJ; Tan XJ; Li DM; Zheng ZH; Lei RX; Peng XM
    Liver Int; 2013 Sep; 33(8):1230-8. PubMed ID: 23617302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Natural history of chronic hepatitis B virus infection from infancy to adult life - the mechanism of inflammation triggering and long-term impacts.
    Wu JF; Chang MH
    J Biomed Sci; 2015 Oct; 22():92. PubMed ID: 26487087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA.
    Martinot-Peignoux M; Lapalus M; Laouénan C; Lada O; Netto-Cardoso AC; Boyer N; Ripault MP; Carvalho-Filho R; Asselah T; Marcellin P
    J Clin Virol; 2013 Oct; 58(2):401-7. PubMed ID: 24004660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein.
    Visvanathan K; Skinner NA; Thompson AJ; Riordan SM; Sozzi V; Edwards R; Rodgers S; Kurtovic J; Chang J; Lewin S; Desmond P; Locarnini S
    Hepatology; 2007 Jan; 45(1):102-10. PubMed ID: 17187404
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection.
    Zheng Q; Zhu YY; Chen J; Ye YB; Li JY; Liu YR; Hu ML; Zheng YC; Jiang JJ
    Clin Exp Immunol; 2015 Jun; 180(3):499-508. PubMed ID: 25639451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early inhibition of hepatocyte innate responses by hepatitis B virus.
    Luangsay S; Gruffaz M; Isorce N; Testoni B; Michelet M; Faure-Dupuy S; Maadadi S; Ait-Goughoulte M; Parent R; Rivoire M; Javanbakht H; Lucifora J; Durantel D; Zoulim F
    J Hepatol; 2015 Dec; 63(6):1314-22. PubMed ID: 26216533
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.